Copyright
©The Author(s) 2024.
World J Gastroenterol. Oct 14, 2024; 30(38): 4175-4193
Published online Oct 14, 2024. doi: 10.3748/wjg.v30.i38.4175
Published online Oct 14, 2024. doi: 10.3748/wjg.v30.i38.4175
Table 1 Functions of N6-methyladenosine regulators
Types | Regulators | Functions | Ref. |
METTL3 | Catalyses m6A modification | [30,31] | |
METTL14 | Provides structural support and recognizes target RNAs | [30,31] | |
WTAP | Contributes to the orientation of MTC | [32,33] | |
VIRMA/KIAA1429 | Recruits m6A complexes to specialized RNA sites | [32,33] | |
m6A writers | ZC3H13 | Bridges WTAP to Nito | [32,33] |
RBM15 | Binds to the m6A complex and recruits to specialized RNA sites | [32,33] | |
CBLL1/HAKAI | Contributes to the stabilization of MTC | [32,34] | |
METTL16 | Catalyses m6A modification | [35] | |
FTO | Affects RNA splicing stabilization and deletes m6A modifications | [36] | |
m6A erasers | ALKBH5 | Regulates RNA export and splicing, and deletes m6A modifications | [36] |
IGF2BPs | Enhances mRNA stability and translation | [37] | |
YTHDC1 | Mediates RNA splicing and export | [38] | |
YTHDC2 | Enhances target RNA translation and reduces RNA abundance | [39] | |
YTHDF1 | Enhances mRNA translation | [40] | |
YTHDF2 | Promotes mRNA degradation | [40] | |
m6A readers | YTHDF3 | Synergizes with YTHDF1 and YTHDF2 to enhance translation and degradation | [40] |
ELF3 | Enhances mRNA translation | [41] | |
FMR1 | Promotes mRNA degradation | [42] | |
HNRNPs | Mediates mRNA splicing and translation | [43] | |
HNRNPA2B1 | Mediates mRNA splicing and miRNA processing | [44] | |
ELAL1/HuR | Improve translation efficiency and stability of mRNA | [45] |
Table 2 The role of the gut microbiota in colorectal cancer
Gut microbiota | Roles | Functions | Mechanism | Ref. |
Coriobacteriaceae | Promote | Tumorigenesis, progression↑ | CPT1A-ERK axis | [68] |
Clostridioides difficile | Promote | Tumorigenesis↑ | Secrete toxin TcdB | [69] |
F. nucleatum | Promote | Tumorigenesis, metastasis↑ | modulate TME | [70,71] |
ETBF | Promote | Progression↑ | Suppress the immune responses | [72] |
Escherichia coli | Promote | Proliferation, progression↑ | Exert toxic effects on DNA | [73] |
Enterococcus faecalis | Promote | Tumorigenesis, progression↑ | Secrete metabolite biliverdin | [74] |
Salmonella enterica | Promote | Tumorigenesis, proliferation↑ | Express secretory protein AvrA | [75] |
Streptococcus bovis/gallolyticus | Promote | Tumorigenesis, progression↑ | Promote inflammatory response | [76] |
Blautia producta | Suppress | Tumorigenesis, progression↓ | Facilitate the immune surveillance | [77] |
Lactobacillus acidophilus, Lactobacillus rhamnosus, and Lactobacillus casei | Suppress | Migration, invasion↓ | Reduce abnormal crypt foci | [78] |
Roseburia intestinalis | Suppress | Tumorigenesis, proliferation↓ | Produce butyrate and induce CD8+ T cells | [79] |
Akkermansia muciniphila | Suppress | Proliferation↓ | Modulate CD8+ T cells | [80] |
Table 3 Relationships among N6-methyladenosine, colorectal cancer, and related mechanisms
m6A regulator | Upstream mechanism | Roles | Functions | Mechanism | Ref. |
METTL3 | Gut microbiota | Oncogene | Glycolysis, chemo-resistance↑ | METTL3↑/LDHA↑ | [100] |
METTL3 | Gut microbiota | Oncogene | Proliferation, migration, invasion↑ | METTL3↑/m6A↑/YTHDF2↑/CRB3↓/Hippo↓ | [55] |
METTL3 | Gut microbiota | Oncogene | Glycolysis, progression↑ | METTL3↑/m6A/GLUT1↑/mTORC1 ↑ | [101] |
METTL3 | Gut microbiota | Oncogene | Invasion, migration↑ | METTL3↑/m6A/circ1662↑/YAP1↑/SMAD3↓ | [102] |
METTL3 | F. nucleatum | Suppressor | Metastasis↑ | METTL3↓/m6A↓/YTHDF2/KIF26B↑ | [24] |
METTL16 | Gut microbiota | Oncogene | Glycolysis, progression↑ | METTL14↑/IGF2BP1/SOGA1↑/PDK4↑ | [83] |
METTL14 | ETBF | Suppressor | Proliferation↑ | METTL14↓/m6A/miR-149-3p↓/PHF5A/KAT2A | [88] |
METTL14 | Gut microbiota | Suppressor | Proliferation, metastasis↑ | METTL14↓/m6A↓/YTHDF2↓/lncRNA XIST↑ | [103] |
METTL14 | Gut microbiota | Suppressor | Migration, invasion, metastasis↑ | METTL14↓/m6A↓/YTHDF2/SOX4↑ | [104] |
ALKBH5 | H3K27 | Oncogene | Glycolysis, progression↓ | ALKBH5↓/JMJD8↓/PKM2↓ | [105] |
ALKBH5 | Oncogene | Proliferation, migration, invasion↑ | ALKBH5↑/YTHDF2/RAB5A↑ | [106] | |
ALKBH5 | Suppressor | Radiosensitivity↑ | ALKBH5↑/YTHDF2/circAFF2↑/Cullin-NEDD8↓ | [107] | |
ALKBH5 | Suppressor | Proliferation, migration, invasion↓ | ALKBH5↑/PHF20↓ | [91] | |
FTO | Oncogene | Chemo-resistance↑ | FTO↑/YTHDF2/SIVA1↓ | [92] | |
FTO | miR-96 | Oncogene | Tumorigenesis, progression↑ | AMPKα2↓/FTO↑/m6A↓/MYC↑ | [93] |
IGF2BP2 | LINC00460 | Oncogene | Proliferation, metastasis↑ | IGF2BP2-DHX9↑/HMGA1↑ | [108] |
YTHDF1 | Oncogene | Tumorigenesis, metastasis↑ | YTHDF1↑/m6A/ARHGEF2↑ | [109] | |
YTHDF2 | miR-6125 | Oncogene | Proliferation, growth↓ | YTHDF2↓/m6A/GSK3β↑ | [110] |
HNRNPA2B1 | MIR100HG | Oncogene | Chemo-resistance, metastasis↑ | hnRNPA2B1↑/m6A/TCF7L2↑ | [111] |
Table 4 Summary of the molecules of action, inhibitory concentration values, and mechanisms of action of existing anticancer drugs for N6-methyladenosine-targeted therapy
Drug | Role in cancer | Cancer type | Target | IC50 | Mechanism | Ref. |
STM2457 | Tumour inhibitor | AML | METTL3 | 16.9 nM | m6A↓/HOXA1018↓/MYC19↓ | [142] |
UZH1a | Tumour inhibitor | AML | METTL3 | 4.6 μM | Inhibits METTL3 catalytic activity and decreases m6A level and mRNA transcription level | [143] |
CS1 | Tumour inhibitor | AML | FTO | m6A↑/LILRB4↓/MYC↓/CEBPA↓/RARA↑/ASB2↑ | [145] | |
FB23 | Tumour inhibitor | AML | FTO | 0.8-1.5 μM | m6A↑/MYC↓/CEBPA↓/RARA↑/ASB2↑ | [148] |
MA | Tumour inhibitor | AML | FTO | 17.4 μM | Binds to FTO and inhibits demethylation | [147] |
R-2HG | Tumour inhibitor | AML | FTO | m6A↑/FTO↓/MYC↓CEBPA↓ | [146] | |
Rhein | Tumour inhibitor | Liver cancer | FTO/ALKBH5 | 30 mM | Competitive binding of FTO to substrate binding sites and increased m6A levels | [149] |
2-[(1-hydroxy-2-oxo-2-phenylethyl) sulfanyl] acetic acid | Tumour inhibitor | AML | ALKBH5 | 0.84 μM | Binds ALKBH5 and decreases m6A levels | [150] |
4-{[(furan-2-yl) methyl]amino}-1,2-diazinane-3,6-dione | Tumour inhibitor | AML | ALKBH5 | 1.79 μM | Binds ALKBH5 and decreases m6A levels | [150] |
- Citation: Jiang TQ, Wang H, Cheng WX, Xie C. Modulation of host N6-methyladenosine modification by gut microbiota in colorectal cancer. World J Gastroenterol 2024; 30(38): 4175-4193
- URL: https://www.wjgnet.com/1007-9327/full/v30/i38/4175.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i38.4175